Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-240, an Allogeneic Cellular Therapy, for the Treatment of Solid Tumors

Daniel Sontupe
Market Access

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition